BMJ (Clinical research ed.)
Audio Summaries

Evaluation of patient centred digital adherence technology for tuberculosis treatment outcomes: pragmatic randomised controlled trial

Aug 6, 2026

The authors aimed to evaluate the effectiveness of a patient-centered digital adherence technology, Tuberculosis Treatment Support Tools (TB-TST), in improving treatment outcomes for individuals with drug-susceptible tuberculosis in Argentina. The study found that the intervention group experienced a higher treatment success rate and lower loss to follow-up compared to the control group, particularly benefiting younger participants and women. These results suggest that digital adherence tools can enhance tuberculosis treatment adherence in low-resource settings, warranting further research on their broader applications and effectiveness.

Comparative effectiveness of azithromycin versus roflumilast in patients with chronic obstructive pulmonary disease: emulated target trial

Aug 5, 2026

The authors aimed to compare the effectiveness of azithromycin versus roflumilast in reducing the risk of moderate or severe exacerbations in patients with chronic obstructive pulmonary disease (COPD). Their study found that azithromycin was associated with a 17% reduction in the hazard of experiencing a first exacerbation compared to roflumilast. This suggests that azithromycin may be a more effective treatment option for managing exacerbations in this patient population.

Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study

Aug 5, 2026

The authors aimed to estimate the reduction in major adverse cardiovascular events (MACE) associated with the addition of tirzepatide to standard care in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Their population-based cohort study found that initiating tirzepatide significantly lowered the risk of MACE compared to sitagliptin, with notable reductions in myocardial infarction and infection-related events. These findings suggest that tirzepatide may offer cardiovascular benefits beyond standard treatment, highlighting its potential role in clinical practice.

Antithrombotic treatment for migraine in patients with patent foramen ovale: multicentre, randomised, active controlled, open label trial

Jul 29, 2026

The authors aimed to evaluate the efficacy and safety of antithrombotic treatments (aspirin, clopidogrel, and rivaroxaban) for migraine prevention in patients with patent foramen ovale (PFO). The study found that all antithrombotic agents were non-inferior to metoprolol in reducing migraine days, with rivaroxaban demonstrating superior efficacy compared to metoprolol without increasing the risk of major bleeding events.

Antihistamines for atopic dermatitis (eczema): systematic review and network meta-analysis of randomised trials

Jul 29, 2026

The authors aimed to systematically evaluate the benefits and harms of adding oral antihistamines for managing atopic dermatitis (eczema) through a network meta-analysis of randomized trials. They found that while antihistamines may slightly reduce atopic dermatitis and itch severity, these effects are clinically insignificant, and first-generation antihistamines are associated with increased cognitive impairment and treatment discontinuation. The study suggests that routine use of antihistamines in atopic dermatitis management is not supported by the evidence.

Investigation and management of breakthrough ischemic stroke in anticoagulated patients with atrial fibrillation

Jul 27, 2026

This review investigates the phenomenon of breakthrough ischemic strokes in patients with atrial fibrillation who are on direct oral anticoagulants, despite appropriate treatment. The authors aim to understand the epidemiology and mechanisms behind these strokes, propose a systematic approach for their investigation, and discuss potential management strategies. They also introduce the AF-BREACH criteria to help identify suitable candidates for future clinical trials.

Early treatment with rasburicase and risk of kidney replacement therapy and death in adults with tumour lysis syndrome: emulated target trial

Jul 23, 2026

The authors aimed to investigate the impact of early rasburicase treatment on the risk of acute kidney injury requiring kidney replacement therapy or death in adults with tumor lysis syndrome (TLS). Their findings indicate that administering rasburicase within 12 hours of TLS onset is associated with a significantly lower risk of these adverse outcomes compared to delayed treatment or no treatment at all. Specifically, early treatment reduced the risk of acute kidney injury or death by approximately one third.

Minimal detectable change of the Patient Health Questionnaire-9, Patient Health Questionnaire-8, and Patient Health Questionnaire-2: individual patient data meta-analysis

Jul 23, 2026

The authors aimed to estimate the minimal detectable change (MDC) for the Patient Health Questionnaire-9 (PHQ-9), PHQ-8, and PHQ-2, examining variations based on participant and study characteristics. Through an individual participant data meta-analysis involving over 42,000 participants, they found that a six-point difference on the PHQ-9 could serve as an appropriate MDC threshold in general practice, with higher thresholds recommended in specialty mental healthcare settings. The study provides insights into the reliability of these questionnaires for detecting meaningful changes in depression symptoms.

Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation

Jul 22, 2026

The authors aimed to investigate the association between glucagon-like peptide-1 (GLP-1) receptor agonists and the risk of hair loss (alopecia) in adults with type 2 diabetes, comparing it to sodium-glucose cotransporter-2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. The study found that the use of GLP-1 receptor agonists was linked to a higher risk of non-scarring alopecia compared to both SGLT-2 and DPP-4 inhibitors, suggesting that while the absolute risk is low, this potential side effect should be considered in treatment decisions.

Contemporary hormonal contraception and colorectal cancer in premenopausal women: nationwide cohort study

Jul 15, 2026

The authors aimed to investigate the impact of various contemporary hormonal contraceptives on the risk of developing colorectal cancer in premenopausal women. Their nationwide cohort study, involving nearly two million women in Denmark, found no significant association between current or recent hormonal contraceptive use and colorectal cancer risk, suggesting that these contraceptives do not contribute to the increasing incidence of the disease in young women.